| Name | 4-Piperidinamine, 1-[3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]-4-methyl- | CAS# | 2160546-07-4 | |
|---|---|---|---|---|
| Price | $700.0/100mg $1200.0/250mg $2400.0/1g | Purity | 98.0% | |
| Stocking Period |
Inquiry | Stock | 3 | |
| Product Webpage: | https://www.dcchemicals.com/product_show-IACS-13909.html | |||
| Detail
Product Information
IACS-13909 is a specific and potent allosteric inhibitor of SHP2 that suppresses the signaling of RTK/MAPK pathway and overcomes multiple mechanisms underlying osimertinib resistance. IACS-13909 potently impedes the proliferation of tumors with a broad spectrum of RTKs as the oncogenic driver. Importantly, in NSCLC models with acquired resistance to osimertinib, IACS-13909 administered as a single agent or in combination with osimertinib potently reduces tumor cell proliferation in vitro and in vivo. Together, our findings provide preclinical evidence for using a SHP2 inhibitor as a therapeutic strategy in acquired EGFR inhibitor-resistant NSCLC. |